Clinical research organisation Novotech has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific CRO industry.
Novotech has been a recipient of the Frost & Sullivan Asia Pacific Best Practices awards since 2006.
Frost & Sullivan identifies companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.
Frost & Sullivan said, “Our approach involves the deployment of best practices and strategic analytics across a value chain. Against this backdrop, Frost & Sullivan recognises Novotech for its valuable achievement. Novotech addresses the global drug development market’s unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation. From feasibility assessments to regulatory submission support, data management, medical monitoring, and project management, the company provides a 360-degree approach to drug development for its biotech clients.”
In response to the Company of the Year Award announcement, Novotech CEO Dr John Moller said this award is a credit to our entire global team with decades of biotech drug development experience.
“Every day our team supports biotech companies in their drug development programs with unparalleled regulatory knowledge, vast site and investigator networks, technology-driven clinical data management, and a project management approach focused on problem-solving, ownership, and flexibility. Our global clients benefit from access to our expert teams in Asia Pacific, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution,” he said.
